Short answer
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on May 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results covered quarter ended March 31, 2026.
Mineralys Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results covered quarter ended March 31, 2026
- Corporate update issued alongside results on May 6, 2026
- Detailed financial figures and operating developments contained in Exhibit 99.1
- Disclosure furnished under Regulation FD, limiting Section 18 liability and automatic incorporation into other filings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mineralys Therapeutics, Inc. 8-K filings
Get the next MLYS 8-K as it lands
Follow MLYS for push alerts, or ask the research agent what this filing means.